Home Alzheimer’s Disease Caron A. Jacobson, MD, on the Interim Phase II ZUMA-5 Study Safety...

Caron A. Jacobson, MD, on the Interim Phase II ZUMA-5 Study Safety and Efficacy Findings

Results from the interim analysis of the phase II ZUMA-5 study, presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program, indicated that axicabtagene ciloleucel (axi-cel) demonstrated significant and durable clinical benefit in patients with relapsed or refractory indolent non-Hodgkin lymphoma. 

Though this particular study requires further follow-up, the investigators suggested that axi-cel may be a promising therapeutic approach for this patient population.

In an interview with CancerNetwork®, Caron A. Jacobson, MD, of the Dana-Farber Cancer Institute, explained the efficacy and safety findings observed in the interim analysis. 


Yep. So, in total 125 patients with follicular lymphoma were in enrolled and treated, and 16 patients with marginal zone lymphoma were enrolled and treated. The way this study was designed is that the…

Continue Reading to the Source


Please enter your comment!
Please enter your name here

Most Popular

Reflections on Living With an Incurable Illness : braincancer

(I’ve checked with the moderators to make sure this is appropriate and a good fit for this subreddit. I'm a very private person, and...

This Foramen Magnum Meningioma almost killed me 18 years ago.

submitted by /u/dkrem Continue Reading to the Source

Patients, Family & Friends, and Healthcare professionals : braincancer

I am currently a PhD student based at the Marie Curie Palliative Care Research Centre at Cardiff University. My PhD is focussed on developing...

32 year old singer Tom Parker of The Wanted diagnosed with stage 4 glioblastoma

submitted by /u/Jexlan Continue Reading to the Source

Recent Comments